Aspirin use is associated with lower prostate cancer risk in male carriers of BRCA mutations

Journal of Genetic Counseling

Volumn 23, Issue 2, 2014, Pages 187-191

  Cossack, Matthew ^a   Ghaffary, Cameron ^a   Watson, Patrice ^a   Snyder, Carrie ^a   Lynch, Henry ^a  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aspirin; BRCA1; BRCA2; Prostate cancer; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID;

ARTICLE; GENETICS; HETEROZYGOTE DETECTION; HUMAN; MALE; MUTATION; PROSTATE TUMOR; TUMOR SUPPRESSOR GENE;

ASPIRIN; GENES, BRCA1; GENES, BRCA2; HETEROZYGOTE DETECTION; HUMANS; MALE; MUTATION; PROSTATIC NEOPLASMS;

EID: 84896985845     PISSN: 10597700     EISSN: 15733599     Source Type: Journal    
DOI: 10.1007/s10897-013-9629-8     Document Type: Article

References (29)

1. Burn, J., Gerdes, A. M., Macrae, F., Mecklin, J. P., Moeslein, G., Olschwang, S., & Bishop, D. T. (2011). Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. The Lancet, 378(9809), 2081-2087.
2. Burn, J., Mathers, J., & Bishop, D. T. (2013). Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC). Recent Results in Cancer Research, 191, 157-183.
3. Carter, B. S., Beaty, T. H., Steinberg, G. D., Childs, B., & Walsh, P. C. (1992). Mendelian inheritance of familial prostate cancer. Proc. Natl. Acad. Sci. USA, 89, 3367-3371.
4. Cuzick, J., Otto, F., & Baron, J. A. (2009). Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. The Lancet Oncology, 10, 501-507.
5. De Nunzio, C., Kramer, G., Marberger, M., Montironi, R., Nelson, W., Schroder, F., & Tubaro, A. (2011). The controversial relationship between benign prostatic hyperplasia and prostate cancer: The role of inflammation. European Urology, 60, 106-117.
6. Edwards, S. M., & Eeles, R. A. (2004). Unravelling the genetics of prostate cancer. American Journal of Medical Genetics. Part C, Seminars in Medical Genetics, 129C, 65-73.
7. Edwards, S. M., Kote-Jarai, Z., Meitz, J., Hamoudi, R., Hope, Q., Osin, P., & Eeles, R. A. (2003). Two Percent of Men with Early-Onset Prostate Cancer Harbor Germline Mutations in the BRCA2 Gene. The American Journal of Human Genetics, 72(1), 1-12.
8. Friedenreich, C. M., McGregor, S. E., Courneya, K. S., Angyalfi, S. J., & Elliott, F. G. (2004). Case-control study of lifetime total physical activity and prostate cancer risk. American Journal of Epidemiology, 159(8), 740-749.
9. Hickey, K., Do, K. A., & Green, A. (2001). Smoking and prostate cancer. Epidemiologic Reviews, 23(1), 115-125.
10. Honda, G. D., Bernstein, L., Ross, R. K., Greenland, S., Gerkins, V., & Henderson, B. E. (1988). Vasectomy, cigarette-smoking, and age at 1st sexual intercourse as risk-factors for prostate-cancer in middle-aged men. British Journal of Cancer, 57, 326-331.
11. Kote-Jarai, K., Leongamornlet, D., Saunders, E., Tymrakiewicz, M., Castro, E., Mahmud, N., et al. (2011). BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients. British Journal of Cancer, 105(8), 1230-1234.
12. Leongamornlert, D., Mahmud, N., Tymrakiewicz, M., Saunders, E., Dadaev, T., Castro, E., & Kote-Jarai, Z. (2012). Germline BRCA1 mutations increase prostate cancer risk. British Journal of Cancer, 106(10), 1697-1701.
13. McLaughlin, J. K., Mandel, J. S., Mehl, E. S., & Blot, W. J. (1990). Comparison of next-of-kin with self-respondents regarding questions on cigarette, coffee, and alcohol consumption. Epidemiology, 1(5), 408-412.
14. O'Neill, G. P., & Ford-Hutchinson, A. W. (1993). Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Letters, 330, 157-160.
15. Ostrand-Rosenberg, S., & Sinha, P. (2009). Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer. The Journal of Immunology, 182(8), 4499-4506.
16. Pienta, K. J., & Esper, P. S. (1993). Risk-factors for prostate cancer. Annals of Internal Medicine, 118, 793-803.
17. Platz, E. A., Leitzmann, M. F., Fisvanathan, K., Rimm, E. B., Stampfer, M. J., Willett, W. C., & Giovannucci, E. (2006). Statin drugs and risk of advanced prostate cancer. Journal of the National Cancer Institute, 98, 1819-1825.
18. Shafique, K., McLoone, P., Qureshi, K., Leung, H., Hart, C., & Morrison, D. S. (2012). Coffee consumption and prostate cancer risk: Further evidence for inverse relationship. Nutrition Journal, 11, 42.
19. Shebl, F. M., Sakoda, L. C., Black, A., Koshiol, J., Andriole, G. L., Grubb, R., & Hsing, A. W. (2012). Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: A PLCO Study. British Journal of Cancer, 107, 207-214.
20. Siegel, R., Naishadham, D., & Jemal, A. (2012). Cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 62, 10-29.
21. Smith, W., DeWitt, D., & Garavito, R. (2000). Cyclooxygenases: Structural, cellular, and molecular biology. Annual Review of Biochemistry, 69, 145-182.
22. Stock, D., Groome, P. A., & Siemens, D. R. (2008). Inflammation and prostate cancer: A future target for prevention and therapy Urologic Clinics of North America, 35, 117-130.
23. Strømsvik, N., Råheim, M., Oyen, N., Engebretsen, L. F., & Gjengedal, E. (2010). Stigmatization and male identity: Norwegian males' experience after identification as BRCA1/2 mutation carriers. Journal of Genetic Counseling, 19, 360-370.
24. Strømsvik, N., Råheim, M., & Gjengedal, E. (2011). Cancer worry among Norwegian male BRCA1/2 mutation carriers. Familial Cancer, 10, 597-603.
25. Thompson, D., & Easton, D. F. (2001). Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. American Journal of Human Genetics, 68, 410-419.
26. Thompson, D., & Easton, D. F. (2002). Cancer incidence in BRCA1 mutation carriers. Journal of the National Cancer Institute, 94, 1358-1365.
27. Thompson, I. M., Goodman, P. J., Tangen, C. M., Lucia, M. S., Miller, G. J., Ford, L. G., & Coltman, C. A. (2003). The influence of finasteride on the development of prostate cancer. The New England Journal of Medicine, 349, 215-224.
28. Tymchuk, C. N., Barnard, R. J., Heber, D., & Aronson, W. J. (2001). Evidence of an inhibitory effect of diet and exercise on prostate cancer cell growth. The Journal of Urology, 166, 1185-1189.
29. Wilson, K. M., Kasperzyk, J. L., Rider, J. R., Kenfield, S., van Dam, R. M., Stampfer, M. J., & Mucci, L. A. (2011). Coffee consumption and prostate cancer risk and progression in the health professionals follow-up study. Journal of the National Cancer Institute, 103, 876-884.